0O8G Stock Overview
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MDxHealth SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.02 |
| 52 Week High | US$4.72 |
| 52 Week Low | US$1.98 |
| Beta | -379681.87 |
| 11 Month Change | 0% |
| 3 Month Change | -3.77% |
| 1 Year Change | 6.33% |
| 33 Year Change | -73.83% |
| 5 Year Change | -80.81% |
| Change since IPO | -95.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0O8G | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | 0.8% |
| 1Y | 6.3% | -20.1% | 6.6% |
Return vs Industry: 0O8G exceeded the UK Biotechs industry which returned -30.1% over the past year.
Return vs Market: 0O8G exceeded the UK Market which returned -0.4% over the past year.
Price Volatility
| 0O8G volatility | |
|---|---|
| 0O8G Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0O8G has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0O8G's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 255 | Mike McGarrity | mdxhealth.com |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA Fundamentals Summary
| 0O8G fundamental statistics | |
|---|---|
| Market cap | €64.93m |
| Earnings (TTM) | -€39.45m |
| Revenue (TTM) | €64.24m |
1.0x
P/S Ratio-1.6x
P/E RatioIs 0O8G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0O8G income statement (TTM) | |
|---|---|
| Revenue | US$70.19m |
| Cost of Revenue | US$26.26m |
| Gross Profit | US$43.93m |
| Other Expenses | US$87.03m |
| Earnings | -US$43.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -1.58 |
| Gross Margin | 62.58% |
| Net Profit Margin | -61.40% |
| Debt/Equity Ratio | 502.3% |
How did 0O8G perform over the long term?
See historical performance and comparison